Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations

Key Takeaway: Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,May 30, 2014/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast its management presentation at the following investor conferences:
• Jefferies 2014 Global Healthcare Conference at8:30 AM Eastern Time on Thursday, June 5, 2014
• 2014 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc., at10:30 AM Eastern TimeonFriday June 13, 2014
The session may be accessed through the Company's web site,www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for 30 days.
Regeneron will no longer be participating in the following previously scheduled investor conference:
• Goldman Sachs 35thAnnual Global Healthcare Conference previously scheduled for2:20 PM Eastern Time(11:20 AM Pacific Time) onTuesday, June 10, 2014

About Regeneron Pharmaceuticals

Regeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visitwww.regeneron.com.
Contact Information:
Manisha Narasimhan, Ph.D. Hala Mirza
Investor Relations Corporate Communications
914.847.5126 914.847.3422
[email protected] [email protected]
Last updated: May 30, 2014